DUBLIN – Avvinity Therapeutics Ltd., a newly created joint venture between Horizon Discovery Group plc and start-up firm Centauri Therapeutics Ltd., is getting up to £5.3 million (US$7.4 million) in series A funding to apply Centauri’s Alphamer anti-infectives technology to immuno-oncology indications.